National Cerebral and Cardiovascular Center   Report issue

Government Phase 2 Phase 3 Phase 4
Founded: Osaka Japan (1966)

Organization Overview

First Clinical Trial
2001
NCT00212030
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrial Fibrillation (Phase 4)

Brain Ischemia (Phase 3)

Cerebral Hemorrhage (Phase 3)

Cerebral Infarction (Phase 4)

Cognitive Dysfunction (Phase 2)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Embolism (Phase 2)

Hemorrhage (Phase 3)

Infarction (Phase 3)

Intracranial Embolism (Phase 2)

Ischemia (Phase 4)

Stroke (Phase 4)

Thrombocytopenia (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 17
  • # of Trial APIs: 22